Moderna Vaccine Study

A vaccine against this pandemic virus.

Moderna vaccine study. Moderna the national institutes of health nih and researchers in the cove study are trying to find a solution to the current pandemic. Learn more about mrna 1273 moderna s covid 19 vaccine candidate. Moderna chief medical officer tal zaks said. Phase 3 study met statistical criteria with a vaccine efficacy of 94 5 p 0 0001 moderna intends to submit for an emergency use authorization eua with u s.

The vaccine was codeveloped by researchers at the national institute of allergy and infectious diseases niaid the trial sponsor and at moderna cambridge ma. The company s ceo stephane bancel called it a game changer. The co principal investigators for the study are hana m. We look forward to beginning our phase iii study of mrna 1273 with some 30 000 participants in july.

The purpose of this study is to test moderna s vaccine candidate that may prevent illness after exposure to the sars cov 2 virus which causes covid 19. Shots health news the vaccine is nearly 95 effective in preventing illness according to an interim analysis of a clinical. Moderna s covid 19 vaccine is nearly 95 effective in preventing illness according to an interim analysis of a clinical test involving 30 000 people. Baden m d principal investigator of the niaid funded harvard hiv vaccine clinical trials unit at brigham and women s hospital in boston.

Moderna is proud to be among the many groups working to respond to this continuing global health emergency. Moderna inc said on thursday it had completed the enrollment of 30 000 participants in a late stage study testing its experimental coronavirus vaccine with over a third of the participants from. Moderna said preliminary phase three trial data shows its coronavirus vaccine is more than 94 effective in preventing covid 19. Moderna is committed to advancing the clinical development of mrna 1273 as safely and quickly as possible to demonstrate our vaccine s ability to significantly reduce the risk of covid 19 disease.

This page summarizes key milestones in our work to advance mrna 1273 our vaccine candidate against the novel coronavirus. El sahly m d principal investigator of the niaid funded infectious diseases clinical research consortium site at baylor college of medicine in houston.